MAL.TO vs. VRNA

Last updated Apr 1, 2026

Compare and contrast key facts about Magellan Aerospace Corporation (MAL.TO) and Verona Pharma plc (VRNA).

Performance

MAL.TO vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a CA$10,000 investment in Magellan Aerospace Corporation (MAL.TO) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

MAL.TO vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MAL.TO Magellan Aerospace Corporation	13.86%	85.92%	29.71%	-20.45%	3.54%	18.19%	-33.84%	-3.75%	-27.23%	3.09%
VRNA Verona Pharma plc	0.00%	123.30%	153.67%	-25.59%	316.55%	-4.87%	19.68%	-43.34%	-11.82%	-18.85%

Different Trading Currencies

MAL.TO is traded in CAD, while VRNA is traded in USD. To make them comparable, the VRNA values have been converted to CAD using the latest available exchange rates.

Fundamentals

Market Cap MAL.TO : CA$1.20B VRNA : $9.72B
EPS MAL.TO : CA$0.69 VRNA : -$0.69
PS Ratio MAL.TO : 1.15 VRNA : 57.97
PB Ratio MAL.TO : 1.46 VRNA : 34.92
Total Revenue (TTM) MAL.TO : CA$1.04B VRNA : $167.65M
Gross Profit (TTM) MAL.TO : CA$144.81M VRNA : $159.52M
EBITDA (TTM) MAL.TO : CA$119.06M VRNA : -$40.86M

Returns By Period

MAL.TO

• 1D: 5.84%
• 1M: -13.93%
• YTD: 13.86%
• 6M: 29.25%
• 1Y: 65.50%
• 3Y*: 42.65%
• 5Y*: 17.16%
• 10Y*: 4.68%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MAL.TO vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MAL.TO

MAL.TO Risk / Return Rank: 83
MAL.TO Sharpe Ratio Rank: 87
MAL.TO Sortino Ratio Rank: 84
MAL.TO Omega Ratio Rank: 80
MAL.TO Calmar Ratio Rank: 85
MAL.TO Martin Ratio Rank: 81

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MAL.TO vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Magellan Aerospace Corporation (MAL.TO) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MAL.TO	VRNA	Difference
Sharpe ratio Return per unit of total volatility	1.65	—	—
Sortino ratio Return per unit of downside risk	2.35	—	—
Omega ratio Gain probability vs. loss probability	1.28	—	—
Calmar ratio Return relative to maximum drawdown	2.95	—	—
Martin ratio Return relative to average drawdown	6.16	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	MAL.TO	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.65	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.53	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.14	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	—	—

Correlation

The correlation between MAL.TO and VRNA is 0.06, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MAL.TO vs. VRNA - Dividend Comparison

MAL.TO's dividend yield for the trailing twelve months is around 0.95%, while VRNA has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MAL.TO Magellan Aerospace Corporation	0.95%	0.94%	0.99%	1.27%	2.60%	4.22%	4.79%	2.88%	2.37%	1.33%	1.33%	1.39%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

Drawdown Indicators

	MAL.TO	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-99.96%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-22.77%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-35.44%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-75.12%	—	—
Current Drawdown Current decline from peak	-96.24%	—	—
Average Drawdown Average peak-to-trough decline	-86.89%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	10.89%	—	—

Volatility

Volatility by Period

	MAL.TO	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.27%	—	—
Volatility (6M) Calculated over the trailing 6-month period	29.23%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	39.93%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.58%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.34%	—	—

Financials

MAL.TO vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Magellan Aerospace Corporation and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

MAL.TO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Magellan Aerospace Corporation reported a gross profit of 45.17M and revenue of 278.33M. Therefore, the gross margin over that period was 16.2%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

MAL.TO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Magellan Aerospace Corporation reported an operating income of 29.07M and revenue of 278.33M, resulting in an operating margin of 10.4%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

MAL.TO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Magellan Aerospace Corporation reported a net income of 10.58M and revenue of 278.33M, resulting in a net margin of 3.8%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.